Laboratory Considerations for Clinical Trials
Science:Life Sciences
In this episode, Drs. Steven Lowes and Barry Jones discuss hybrid assays, combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS). This is a growing area of opportunity for protein bioanalysis.
Topics covered include:
...I think that fundamental point about more sensitivity, and associated with that is more selectivity, is going to be part of the future adoption of these hybrid assays. We have needs already, we can see needs for looking at quantifying proteins in very small samples, say tissue biopsies. - Steven Lowes
Learn more at Q2labsolutions.com.
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision (Article in Clinical Chemistry)
What is the Role of Digital Pathology in Clinical Trials
AI in Pathology: Advancements, Challenges, and the Road Ahead
Flow Cytometry as an IVD technology for Companion Diagnostics
Flexible Approaches for Biotech Companies in Clinical Trials
Risk Management for Biotech Companies in Clinical Trials
3 Things to Consider in Preparation for Your Biotech Testing or Trial
Hybrid assays: an interview with Barry Jones and Adriane Spytko
Managing Sample Data from Vendors
Automation within an ADME Laboratory
Bioanalytical Automation of Samples
Consent Tracking for Clinical Samples
Tracking Clinical Trial Samples
Avoiding Canceled Tests in Pediatric Samples
Covid Vaccine Testing
High Throughput ADME Testing
Liquid Biopsy Collection in Clinical Development Programs
An Next Generation Sequencing Approach to Influenza Vaccine Development
Standardization of Tumor Mutational Burden by Alignment to Reference Standards
Monitoring the Tumor Micro-environment with Flow Cytometry - Mark Edinger
Create your
podcast in
minutes
It is Free
Short Wave
Stuff To Blow Your Mind
Unexplainable
Speaking of Psychology
The Science of Life with Dr. Raven Baxter